Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Solomon

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Nature Reviews. Disease Primers|August 14, 2024
Heart failure with preserved ejection fractionCarine E Hamo, Colette DeJong, Nick Hartshorne-Evans, et al.
Journal of Cardiac Failure|November 30, 2010
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson, Scott Solomon, Laura Angelici, et al.
European Heart Journal|November 4, 2004
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEileen O'Meara, Scott Solomon, John McMurray, et al.
Journal of Biomechanics|May 14, 2013
Comparative numerical study on left ventricular fluid dynamics after dilated cardiomyopathyJan O Mangual, Elisabeth Kraigher-Krainer, Alessio De Luca, et al.
Hypertension (Dallas, Tex. : 1979)|June 16, 2020
Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart FailureKanako Teramoto, Wilson Nadruz Junior, Kunihiro Matsushita, et al.
European Journal of Heart Failure|April 30, 2015
Early intervention and long-term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptomsRomana Herscovici, Valentina Kutyifa, Alon Barsheshet, et al.
American Heart Journal|May 15, 2018
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF)James L Januzzi, Javed Butler, Emmanuel Fombu, et al.
Journal of the American College of Cardiology|April 25, 2006
Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarctionPowell Jose, Charles Tomson, Hicham Skali, et al.
Circulation. Heart Failure|June 15, 2016
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialAkshay S Desai, Scott Solomon, Brian Claggett, et al.
Circulation. Heart Failure|December 3, 2015
Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”Hicham Skali, Amil Shah, Gupta, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Nature Reviews. Disease Primers|August 14, 2024
Heart failure with preserved ejection fractionCarine E Hamo, Colette DeJong, Nick Hartshorne-Evans, et al.
Journal of Cardiac Failure|November 30, 2010
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson, Scott Solomon, Laura Angelici, et al.
European Heart Journal|November 4, 2004
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEileen O'Meara, Scott Solomon, John McMurray, et al.
Journal of Biomechanics|May 14, 2013
Comparative numerical study on left ventricular fluid dynamics after dilated cardiomyopathyJan O Mangual, Elisabeth Kraigher-Krainer, Alessio De Luca, et al.
Hypertension (Dallas, Tex. : 1979)|June 16, 2020
Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart FailureKanako Teramoto, Wilson Nadruz Junior, Kunihiro Matsushita, et al.
European Journal of Heart Failure|April 30, 2015
Early intervention and long-term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptomsRomana Herscovici, Valentina Kutyifa, Alon Barsheshet, et al.
American Heart Journal|May 15, 2018
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF)James L Januzzi, Javed Butler, Emmanuel Fombu, et al.
Journal of the American College of Cardiology|April 25, 2006
Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarctionPowell Jose, Charles Tomson, Hicham Skali, et al.
Circulation. Heart Failure|June 15, 2016
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialAkshay S Desai, Scott Solomon, Brian Claggett, et al.
Circulation. Heart Failure|December 3, 2015
Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”Hicham Skali, Amil Shah, Gupta, et al.
Pageof 12